A Phase III Study of Chemotherapy and Chemoradiotherapy With or Without HyperAcute-Pancreas (Algenpantucel-L) Immunotherapy in Subjects with Surgically Resected Pancreatic Cancer
Phase of Trial: Phase III
Latest Information Update: 29 Sep 2016
At a glance
- Drugs Algenpantucel-L (Primary) ; Fluorouracil; Gemcitabine
- Indications Pancreatic cancer
- Focus Registrational; Therapeutic Use
- Acronyms IMPRESS
- Sponsors NewLink Genetics Corporation
- 20 Sep 2016 Status changed from active, no longer recruiting to completed.
- 09 May 2016 Results published in a NewLink Genetics Corporation media release.
- 09 May 2016 Primary endpoint (Overall survival) has not been met, according to a NewLink Genetics Corporation media release.
Most Recent Events
Table of Contents
- At a glance
- Trial Overview
- Trial Details
- Trial Centres
- Trial History